In contrast, we have evaluated the activation specific phosphorylation of NTKD and confirmed that RSKs were activated in several leukemic and model cell lines expressing FLT3-ITD, BCR/ABL, or JAK2-V617F, as well as in the primary FLT3-ITD-positive AML cells we could examine (Figure 1B, Figure 2D,F and Figure S1E). Here, JAK2 is linked to acute myeloid leukemia.